SPOTLIGHT: Chutes & Ladders: Anadys CEO to step down

San Diego-based Anadys Pharmaceuticals says its CEO is stepping down to take a job at a venture capital company. Kleanthis Xanthopoulos is joining Enterprise Partners as a managing partner. Xanthopoulos will stay on as a board member. Anadys inked a deal with Novartis last year to develop the hepatitis C therapy ANA975. Report

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.